F.D.A. to Relabel Leucovorin for Autism Treatment
F.D.A. to Relabel Leucovorin for Autism Treatment
The F.D.A. announced Monday that it would change the drug’s label to reflect potential benefits in reducing autism symptoms.
Read the full article on NY Times Science
Truth Analysis
Analysis Summary:
The article appears mostly accurate, reporting on the FDA's decision to relabel Leucovorin for autism treatment. There is a slight positive slant towards the potential benefits of the drug. The core claim is supported by multiple sources, although the extent of the benefits may be overstated.
Detailed Analysis:
- Claim: The F.D.A. announced Monday that it would change the drug’s label to reflect potential benefits in reducing autism symptoms.
- Verification Source #1: Confirms the FDA is approving a drug to treat autism symptoms.
- Verification Source #3: Mentions leucovorin as a treatment for children with cerebral folate deficiency and autistic symptoms, suggesting FDA recognition.
- Assessment: Supported
Supporting Evidence/Contradictions:
- Source 1 confirms the FDA action: "FDA to approve drug to treat autism symptoms"
- Source 3 mentions "leucovorin as a treatment for children with cerebral folate deficiency and autistic symptoms."